Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Cogstate Ltd ( (AU:CGS) ) is now available.
Cogstate Ltd has upgraded its financial guidance for the fiscal year ending June 30, 2025, citing strong performance and an improved outlook. The company anticipates a significant revenue increase of 20% to 24% compared to the previous year, with full-year revenue expected to reach between $52 million and $54 million. Profit before tax is also projected to rise substantially, with an improvement of 69% to 97% over the prior year. This positive financial outlook reflects Cogstate’s strengthened position in the neuroscience technology industry, potentially benefiting stakeholders and enhancing its market presence.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company focused on optimizing brain health assessments to advance new medicine development and enable earlier clinical insights in healthcare. The company offers rapid, reliable, and sensitive computerized cognitive tests and electronic clinical outcome assessment solutions, supporting clinical trials with quality assurance services and advanced analytics. Cogstate serves biopharmaceutical companies, academic institutions, and healthcare providers, aiming to provide accurate, self-administered digital cognitive measures.
YTD Price Performance: 33.49%
Average Trading Volume: 114,946
Technical Sentiment Signal: Buy
Current Market Cap: A$235.4M
Learn more about CGS stock on TipRanks’ Stock Analysis page.